Clinical trial
Safety, Tolerability and Immunogenicity of Two Different Formulations of…
NCT00433914 · Novartis Vaccines, Industry · Completed
Key facts
| NCT number | NCT00433914 |
|---|---|
| Title | Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants |
| Official title | A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, When Administered to Healthy Infants 6-8 Months Old |
| Lead sponsor | Novartis Vaccines, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Meningococcal Disease |
| Intervention type | Biological |
| Interventions | rMenB, rMenB+OMV |
| Enrollment | 60 |
| Start date | Feb 1, 2007 |
| Primary completion | Dec 1, 2007 |
| Completion | Jul 1, 2008 |
| First posted | Feb 12, 2007 |
| Last update posted | Mar 6, 2015 |
| Countries | United Kingdom |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: